Candel Therapeutics

Candel Therapeutics EBIT per Employee

The EBIT per Employee of Candel Therapeutics (CADL) as of Nov 17, 2026 is -877,563.64 USD. In the previous year, EBIT per Employee was -965,218.18 USD — a change of -9.08% (higher).

EBIT per Employee

-877,563.64USD

YoY

-9.08%

Last updated:

EBIT per Employee of Candel Therapeutics is 2025 -877,563.64 USD. EBIT per Employee of Candel Therapeutics was 2024 -965,218.18 USD. It decreases by -9.08% higher compared to the previous year.

The Candel Therapeutics EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-164,309.09 USD
Jan 1, 2020
-251,090.91 USD
Jan 1, 2021
-655,836.36 USD
Jan 1, 2022
-630,436.36 USD
Jan 1, 2023
-698,018.18 USD
Jan 1, 2024
-965,218.18 USD
Jan 1, 2025
-877,563.64 USD
The Candel Therapeutics EBIT per Employee history
YEAREBIT per EmployeeYoY
-877,563.64USD-9.08%
-965,218.18USD+38.28%
-698,018.18USD+10.72%
-630,436.36USD-3.87%
-655,836.36USD+161.19%
-251,090.91USD+52.82%
-164,309.09USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Candel Therapeutics Stock analysis

What does Candel Therapeutics do? Candel Therapeutics, Inc. develops viral immunotherapies for cancer treatment, focusing on engineered viruses that induce immunogenic death in cancer cells. The company's two clinical-stage product candidates are CAN-2409, an adenovirus-based construct encoding thymidine kinase, and CAN-3110, leveraging its enLIGHTEN Discovery Platform for HSV-based therapies. The firm commercializes these viral immunotherapies through its two platforms, targeting solid tumors with adenovirus and HSV constructs. Its products are developed for patients seeking advanced cancer treatments, with the company operating in the late clinical stage of development. The company generates revenue through the development and commercialization of its viral immunotherapies, including CAN-2409 and CAN-3110, which are in clinical stages. Its enLIGHTEN Discovery Platform supports the creation of new viral immunotherapies for solid tumors, enabling the firm to advance its pipeline. The products are designed to release tumor neo-antigens and create a pro-inflammatory microenvironment, addressing unmet needs in cancer therapy. Candel Therapeutics targets patients and healthcare providers in the oncology sector seeking innovative treatment options. Candel Therapeutics, Inc. focuses on late clinical stage biotechnology, with its two product candidates in development. The company's platforms are based on genetically modified adenovirus and herpes simplex virus constructs, which are used to develop its viral immunotherapies. The firm's revenue model relies on the progression of its clinical-stage products toward commercialization, with CAN-2409 and CAN-3110 being the primary focus for future revenue streams. The company's target market includes patients with solid tumors requiring novel immunotherapies. Candel Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Candel Therapeutics stock

EBIT per Employee of Candel Therapeutics is -877,563.64 USD in 2025.

EBIT per Employee of Candel Therapeutics changed from -965,218.18 USD to -877,563.64 USD, representing a -9.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Candel Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Candel Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Candel Therapeutics

All Key Metrics — Candel Therapeutics